KR101312579B1 - 프로스타글란딘 ｅ2의 생산과 관련된 질환 치료용3-아미노카보졸의 벤조일 유도체의 용도 - Google Patents

프로스타글란딘 ｅ2의 생산과 관련된 질환 치료용3-아미노카보졸의 벤조일 유도체의 용도 Download PDF

Info

Publication number
KR101312579B1
KR101312579B1 KR1020077029661A KR20077029661A KR101312579B1 KR 101312579 B1 KR101312579 B1 KR 101312579B1 KR 1020077029661 A KR1020077029661 A KR 1020077029661A KR 20077029661 A KR20077029661 A KR 20077029661A KR 101312579 B1 KR101312579 B1 KR 101312579B1
Authority
KR
South Korea
Prior art keywords
production
pge
disease
prostaglandin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077029661A
Other languages
English (en)
Korean (ko)
Other versions
KR20080018898A (ko
Inventor
로렌조 폴렌자니
죠르지나 만가노
이사벨라 콜레타
마리아 알레산드라 알리시
니콜라 카졸라
구이도 푸로티
카테리나 마우게리
Original Assignee
아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 filed Critical 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Publication of KR20080018898A publication Critical patent/KR20080018898A/ko
Application granted granted Critical
Publication of KR101312579B1 publication Critical patent/KR101312579B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020077029661A 2005-05-19 2006-05-03 프로스타글란딘 ｅ2의 생산과 관련된 질환 치료용3-아미노카보졸의 벤조일 유도체의 용도 Expired - Fee Related KR101312579B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000909A ITMI20050909A1 (it) 2005-05-19 2005-05-19 Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
ITMI2005A000909 2005-05-19
PCT/EP2006/004348 WO2006122680A1 (en) 2005-05-19 2006-05-03 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)

Publications (2)

Publication Number Publication Date
KR20080018898A KR20080018898A (ko) 2008-02-28
KR101312579B1 true KR101312579B1 (ko) 2013-09-30

Family

ID=35219704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077029661A Expired - Fee Related KR101312579B1 (ko) 2005-05-19 2006-05-03 프로스타글란딘 ｅ2의 생산과 관련된 질환 치료용3-아미노카보졸의 벤조일 유도체의 용도

Country Status (23)

Country Link
US (1) US8686021B2 (https=)
EP (1) EP1881826B1 (https=)
JP (1) JP5086991B2 (https=)
KR (1) KR101312579B1 (https=)
CN (1) CN101166528B (https=)
AR (1) AR054126A1 (https=)
AT (1) ATE473739T1 (https=)
AU (1) AU2006246688B2 (https=)
BR (1) BRPI0609718A2 (https=)
CA (1) CA2604562C (https=)
DE (1) DE602006015457D1 (https=)
DK (1) DK1881826T3 (https=)
EA (1) EA012724B1 (https=)
ES (1) ES2347174T3 (https=)
GE (1) GEP20094738B (https=)
IL (1) IL186072A (https=)
IT (1) ITMI20050909A1 (https=)
MX (1) MX2007013491A (https=)
PL (1) PL1881826T3 (https=)
PT (1) PT1881826E (https=)
SI (1) SI1881826T1 (https=)
UA (1) UA94044C2 (https=)
WO (1) WO2006122680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
EP2119705A1 (en) 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
US8792839B2 (en) 2009-05-14 2014-07-29 Qualcomm Incorporated Allocating transmit power among multiple air interfaces

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030003215A (ko) * 2002-12-23 2003-01-09 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도
KR20030042344A (ko) * 2001-11-22 2003-05-28 한국생명공학연구원 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
CA2381111A1 (en) * 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
DE10125961A1 (de) * 2001-05-29 2002-12-12 Boehringer Ingelheim Int Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden
CA2403307A1 (en) * 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030042344A (ko) * 2001-11-22 2003-05-28 한국생명공학연구원 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제
KR20030003215A (ko) * 2002-12-23 2003-01-09 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도

Also Published As

Publication number Publication date
EA200702534A1 (ru) 2008-04-28
AU2006246688B2 (en) 2011-09-22
UA94044C2 (ru) 2011-04-11
AU2006246688A1 (en) 2006-11-23
BRPI0609718A2 (pt) 2011-10-18
MX2007013491A (es) 2008-01-24
US20080287518A1 (en) 2008-11-20
KR20080018898A (ko) 2008-02-28
EA012724B1 (ru) 2009-12-30
SI1881826T1 (sl) 2010-10-29
CA2604562C (en) 2013-09-17
PL1881826T3 (pl) 2010-12-31
ATE473739T1 (de) 2010-07-15
EP1881826B1 (en) 2010-07-14
ITMI20050909A1 (it) 2006-11-20
CN101166528A (zh) 2008-04-23
ES2347174T3 (es) 2010-10-26
DE602006015457D1 (de) 2010-08-26
CN101166528B (zh) 2011-06-15
IL186072A0 (en) 2008-08-07
PT1881826E (pt) 2010-08-05
DK1881826T3 (da) 2010-11-01
CA2604562A1 (en) 2006-11-23
JP5086991B2 (ja) 2012-11-28
IL186072A (en) 2012-05-31
HK1119571A1 (en) 2009-03-13
AR054126A1 (es) 2007-06-06
JP2008540591A (ja) 2008-11-20
GEP20094738B (en) 2009-07-27
WO2006122680A1 (en) 2006-11-23
EP1881826A1 (en) 2008-01-30
US8686021B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
JP5922116B2 (ja) 複数のプロスタグランジン受容体で作用する全般的な抗炎症反応をもたらす化合物
CN103249408A (zh) 利用多不饱和长链酮类的类风湿性关节炎治疗
JP2004501145A (ja) 向精神作用をもたない新規なカンナビノイド
KR102466932B1 (ko) 약학적 조성물의 제조에서의 사이토크롬 bc1 복합체 저해제의 용도
FR2685869A1 (fr) Compositions therapeutiques a base d'inhibiteurs mixtes de la no synthase et de la cyclooxygenase.
KR20180049144A (ko) 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
US20070213369A1 (en) Novel non-psychotropic cannabinoids
PT1303265E (pt) ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
Srour et al. Synthesis, anti-inflammatory properties, molecular modelling and potential COX-2, TNF-α, PGE2 and IL1β inhibitors of pyrazole-based scaffolds
Bülbül et al. Microsomal prostaglandin E2 synthase-1 as a new macromolecular drug target in the prevention of inflammation and cancer
La Corte et al. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders
KR101312579B1 (ko) 프로스타글란딘 ｅ2의 생산과 관련된 질환 치료용3-아미노카보졸의 벤조일 유도체의 용도
WO2009016081A2 (en) Benzoind0l-2-one derivatives for use in therapy
JPH10511978A (ja) アルツハイマー病の治療用薬剤
MXPA06004434A (es) Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.
HUP9904696A2 (hu) COX-2 Enzim indén-típusú inhibitorai
Krowicki Involvement of hindbrain and peripheral prostanoids in gastric motor and cardiovascular responses to delta-9-tetrahydrocannabinol in the rat
RU2336872C2 (ru) Аннелированные пиррольные соединения как ингибиторы протонового насоса для лечения язвы
HK1119571B (en) Use of a benzoyl derivative of 3-aminocarbazole in manufacture of a medicament in the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
JPH06509110A (ja) 胃及び十二指腸障害を治療する方法及び組成物並びに新規なｐｇｅ↓２誘導体
MODEL Pharmaceutical Sciences
RU2772907C2 (ru) Соединение гидрокситриазина и его применение в медицинских целях
WO2011046200A1 (ja) 分化誘導因子又はその類縁体を含有する抗炎症剤
TW200530219A (en) Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160713

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170824

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180924

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180924

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301